1. Home
  2. KOD vs XRAY Comparison

KOD vs XRAY Comparison

Compare KOD & XRAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$34.16

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo DENTSPLY SIRONA Inc.

XRAY

DENTSPLY SIRONA Inc.

HOLD

Current Price

$10.14

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOD
XRAY
Founded
2009
1899
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.6B
IPO Year
2018
2009

Fundamental Metrics

Financial Performance
Metric
KOD
XRAY
Price
$34.16
$10.14
Analyst Decision
Buy
Hold
Analyst Count
7
14
Target Price
$35.43
$14.58
AVG Volume (30 Days)
636.6K
5.7M
Earning Date
05-14-2026
05-05-2026
Dividend Yield
N/A
5.58%
EPS Growth
N/A
33.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.43
$9.41
52 Week High
$47.84
$17.09

Technical Indicators

Market Signals
Indicator
KOD
XRAY
Relative Strength Index (RSI) 45.85 45.42
Support Level $32.93 $9.57
Resistance Level $46.72 $10.65
Average True Range (ATR) 2.56 0.46
MACD -0.01 0.08
Stochastic Oscillator 56.23 56.61

Price Performance

Historical Comparison
KOD
XRAY

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

About XRAY DENTSPLY SIRONA Inc.

Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).

Share on Social Networks: